Last 27.75 INR
Change Today -0.80 / -2.80%
Volume 4.3M
MRKS On Other Exchanges
Symbol
Exchange
Natl India
As of 7:06 AM 07/9/14 All times are local (Market data is delayed by at least 15 minutes).

marksans pharma ltd (MRKS) Snapshot

Open
28.10
Previous Close
28.55
Day High
29.90
Day Low
26.55
52 Week High
07/3/14 - 32.00
52 Week Low
09/2/13 - 6.05
Market Cap
10.7B
Average Volume 10 Days
3.3M
EPS TTM
1.87
Shares Outstanding
385.3M
EX-Date
--
P/E TM
14.8x
Dividend
0.10
Dividend Yield
--
Current Stock Chart for MARKSANS PHARMA LTD (MRKS)

Related News

No related news articles were found.

marksans pharma ltd (MRKS) Related Businessweek News

No Related Businessweek News Found

marksans pharma ltd (MRKS) Details

Marksans Pharma Limited, through its subsidiaries, develops, manufactures, and sells branded formulations and generic pharmaceutical products in India and internationally. The company provides branded formulations with a primary focus on oncology, critical care, nuero-psychiatrist, CVS, anti-diabetic, and pain management. It also manufactures and distributes over-the-counter pharmaceutical products in the areas of cough and cold remedies, galenicals, vitamins, palliative and healthcare items, oils, antiseptics, and disinfectants; and offers contract research and manufacturing services to global pharmaceutical companies. The company was formerly known as Glenmark Laboratories Ltd. and changed its name to Marksans Pharma Limited in October 2005. Marksans Pharma Limited incorporated in 2001 and is based in Mumbai, India.

Founded in 2001

marksans pharma ltd (MRKS) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

marksans pharma ltd (MRKS) Key Developments

Marksans Pharma Ltd. Recommends Dividend

Marksans Pharma Ltd. in its board meeting held on May 29, 2014, has recommended dividend of 10% which is INR 0.10 per equity share of INR 1 each face value subject to the approval of shareholders in the ensuing Annual General Meeting.

Marksans Pharma Ltd. Reports Audited Consolidated and Standalone Earnings Results for the Fourth Quarter and Year Ended March 31, 2014

Marksans Pharma Ltd. reported audited consolidated and standalone earnings results for the fourth quarter and year ended March 31, 2014. For the quarter, on consolidated basis, the company reported net sales /income from operations of INR 158.863 million compared to INR 123.90 million a year ago. Profit from operations before other income finance cost and exceptional items was INR 20.678 million compared to INR 40.615 million a year ago. Profit from ordinary activities before tax was INR 16.969 million against INR 36.626 million a year ago. Net profit for the period was INR 10.938 million or INR 0.28 per basic and diluted share after extraordinary items compared to INR 41.905 million or INR 1.06 per basic and diluted share after extraordinary items a year ago. For the year, on consolidated basis, the company reported net sales /income from operations of INR 629.997 million compared to INR 438.422 million a year ago. Profit from operations before other income finance cost and exceptional items was INR 105.545 million compared to INR 58.142 million a year ago. Profit from ordinary activities before tax was INR 86.412 million against INR 43.546 million a year ago. Net profit for the period was INR 73.625 million or INR 1.87 per basic and diluted share after extraordinary items compared to INR 48.825 million or INR 1.19 per basic and diluted share after extraordinary items a year ago. EBITDA grew by 64.32% to INR 1,212.40 million for the year. For the quarter, on standalone basis, the company reported net sales /income from operations of INR 83.670 million compared to INR 58.671 million a year ago. Profit from operations before other income finance cost and exceptional items was INR 11.612 million compared to INR 30.016 million a year ago. Profit from ordinary activities before tax was INR 8.140 million against INR 27.032 million a year ago. Net profit for the period was INR 5.288 million or INR 0.14 per basic and diluted share before and after extraordinary items compared to INR 37.010 million or INR 0.96 per basic and diluted share before and after extraordinary items a year ago. For the year, on standalone basis, the company reported net sales /income from operations of INR 314.945 million compared to INR 192.297 million a year ago. Profit from operations before other income finance cost and exceptional items was INR 78.473 million compared to INR 39.738 million a year ago. Profit from ordinary activities before tax was INR 63.260 million against INR 29.606 million a year ago. Net profit for the period was INR 55.558 million or INR 1.44 per basic and diluted share before and after extraordinary items compared to INR 39.584 million or INR 1.03 per basic and diluted share before and after extraordinary items a year ago.

Marksans Pharma Ltd., Board Meeting, May 29, 2014

Marksans Pharma Ltd., Board Meeting, May 29, 2014. Agenda: To consider and approve audited consolidated and standalone earnings results for the fourth quarter and year ended March 31, 2014; and to recommend dividend of 10% which is INR 0.10 per equity share of INR 1/- each face value.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MRKS:IN 27.75 INR -0.80

MRKS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MRKS.
View Industry Companies
 

Industry Analysis

MRKS

Industry Average

Valuation MRKS Industry Range
Price/Earnings 15.3x
Price/Sales 1.7x
Price/Book 7.6x
Price/Cash Flow 12.6x
TEV/Sales 1.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MARKSANS PHARMA LTD, please visit www.marksanspharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.